In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib ...

Patty said that for caregivers, it’s essential to lean on the care team for information specific to the procedure, medication ...

The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

Accelerated approval targets R/R MCL after prior BTK inhibition, addressing an area of high unmet need with limited established salvage standards. Phase 1/2 data at 320 mg QD showed ORR 52.4% and CR ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Cleveland Browns owners recently made a large donation for cancer research. Dee Haslam lives daily with a rare blood cancer ...

Central nervous system (CNS) involvement by CLL is rare. We report a non-treated CLL patient with low-risk factors, but showed leptomeningeal involvement during/after neuroborreliosis and EBV ...